The number of people with susceptibility test result for rifampicin in Mongolia
Mongolia: The number of people with susceptibility test result for rifampicin was 100 in 2021. ▲ Rising
Latest (2021)
100
Change on year
unchanged
World rank
2nd
of 146 countries
All-time high
100
in 2020
All-time low
60.73
in 2017
Years of data
5
2017–2021
The number of people with susceptibility test result for rifampicin in Mongolia, 2017–2021
Source: World Health Organization, Global Health Observatory.
Analysis
In 2021, the number of people with susceptibility test result for rifampicin in Mongolia stood at 100. That is the highest value across all 5 years on record.
That represents a change of up 64.7% over five years.
Mongolia ranks 2nd of 146 countries on this measure, in the top 10%.
The number of people with susceptibility test result for rifampicin in Mongolia, year by year
| Year | Value | Change |
|---|---|---|
| 2017 | 60.73 | — |
| 2018 | 80.54 | +32.6% |
| 2019 | 82.65 | +2.6% |
| 2020 | 100 | +21.0% |
| 2021 | 100 | +0.0% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2010s | 74.64 | 60.73 | 82.65 | 3 |
| 2020s | 100 | 100 | 100 | 2 |
Countries ranked near Mongolia
- 1 Italy 115.63 compare
- 2 Northern Mariana Islands 100 compare
- 2 Jamaica 100 compare
- 2 Lao People's Democratic Republic 100 compare
- 2 Israel 100 compare
- 2 Qatar 100 compare
- 2 Bahamas 100 compare
- 2 Brunei Darussalam 100 compare
- 2 Tonga 100 compare
- 2 Armenia 100 compare
- 2 Palau 100 compare
- 2 Tuvalu 100 compare
- 2 Uzbekistan 100 compare
- 2 Tajikistan 100 compare
- 2 Chad 100 compare
- 2 Bermuda 100 compare
- 2 Mauritius 100 compare
- 2 Eswatini 100 compare
- 2 Belarus 100 compare
- 2 New Caledonia 100 compare
- 2 Andorra 100 compare
- 2 Montenegro 100 compare
- 2 Naoero 100 compare
- 2 Micronesia, Federated States of 100 compare
- 2 Lithuania 100 compare
- 2 Seychelles 100 compare
- 2 Marshall Islands 100 compare
- 2 Saint Lucia 100 compare
- 2 Kuwait 100 compare
- 2 North Macedonia 100 compare
More health data for Mongolia
- Un projection of annual infant deaths, annual growth rate -1.56 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate 0.6056 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 847.3 deaths per 1,000 people (2090)
- Number of infants who die before age 1 63 deaths (2100)
- Neonatal tetanus - number of reported cases, gaps filled 0 (2025)
- Population ages 00-04, female, annual growth rate -3.44 % change on previous year (2025)
- Population ages 00-04, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 00-04, female, per capita 0.0458 units per person (2025)
- Population ages 00-04, male, annual growth rate -3.5 % change on previous year (2025)
- Population ages 00-04, male, per unit of GDP 0 units per US$ of GDP (2025)
Frequently asked questions
- What is the number of people with susceptibility test result for rifampicin in Mongolia?
- The number of people with susceptibility test result for rifampicin in Mongolia was 100 in 2021, according to World Health Organization, Global Health Observatory.
- What is the highest the number of people with susceptibility test result for rifampicin recorded in Mongolia?
- The highest recorded value was 100 in 2020.
- What is the lowest the number of people with susceptibility test result for rifampicin recorded in Mongolia?
- The lowest recorded value was 60.73 in 2017.
- How does Mongolia rank for the number of people with susceptibility test result for rifampicin?
- Mongolia ranks 2nd out of 146 countries with data for 2021.
- Where does this Mongolia data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.. Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 5 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).